Skip Navigation


NDT Advance Access originally published online on May 25, 2007
Nephrology Dialysis Transplantation 2007 22(8):2354-2358; doi:10.1093/ndt/gfm313
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/8/2354    most recent
gfm313v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Westhoff, T. H.
Right arrow Articles by Budde, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Westhoff, T. H.
Right arrow Articles by Budde, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

The impact of FTY720 (fingolimod) on vasodilatory function and arterial elasticity in renal transplant patients

Timm H. Westhoff1, Sven Schmidt1, Petra Glander2, Lutz Liefeld2, Sebastian Martini2, Gerd Offermann1, Hans H. Neumayer2, Walter Zidek1, Markus van der Giet1,* and Klemens Budde2,*

1Centrum 10 – Nephrology, Charité – Campus Benjamin Franklin and 2Department of Nephrology, Charité – Campus Mitte, Berlin, Germany

Correspondence and offprint requests to: Dr Timm H. Westhoff, Medizinische Klinik IV – Nephrology, Charité – Campus Benjamin Franklin, Hindenburgamm 30, 12200 Berlin, Germany. Email: timm.westhoff{at}charite.de



  Abstract

Background. FTY720 has recently demonstrated a similar efficacy in prevention of acute graft rejection compared with mycophenolate mofetil (MMF) in a large phase III trial of de novo renal transplant recipients. Creatinine clearance, however, was significantly lower in FTY720-treated patients. In the present study, we examined the impact of FTY720 on vascular function in a subgroup of patients of this trial.

Methods. Eighteen patients (12 FTY720, 6 MMF) agreed to be enrolled for an analysis of vascular function. Vascular measurements were performed 1.5 years post-transplant and were repeated 3 months after conversion of the patients from FTY720 to MMF. Arterial stiffness was assessed as augmentation index (AI75); endothelium-dependent and -independent vasodilation were measured sonographically as flow-mediated dilation (FMD) and as vasodilation after application of glyceroltrinitrate (GTN).

Results. Conversion from 2.5 mg FTY720 to MMF led to a significant improvement of FMD (5.40 ± 1.84 vs 7.77 ± 3.36%, P 0.02). AI75 and GTN tended to be higher after conversion without reaching significance (83 ± 20.43 vs 78.69 ± 15.39%, P 0.06; 13.76 ± 4.52 vs 17.39 ± 3.76%, P 0.07). In the MMF group, AI75, FMD and GTN did not significantly change during the observation period.

Conclusion. The present study constitutes the first analysis of the impact of FTY720 on vascular function in humans and reveals an improvement of arterial vasodilatory function after discontinuation of FTY720 in de novo renal transplant recipients on cyclosporine.

Keywords: FTY720; renal transplantation; endothelial function; arterial elasticity

*Authors contributed equally to the work.

Received for publication: 23. 3.07
Accepted in revised form: 26. 4.07


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.